AstraZeneca’s Symbicort On Advair’s Heels With COPD Approval
Executive Summary
Symbicort's rapid onset of action and lack of pneumonia signal could be competitive advantages as the drug enters the market with its newly approved use for chonic obstructive pulmonary disease
You may also be interested in...
BI's Spiriva HandiHaler Joins GSK's Advair Diskus In COPD Exacerbations Reduction Claim
The steroid-free, long-acting anticholinergic gains another selling point as others ready drugs for the $7 billion to $8 billion COPD market.
Spiriva Finds COPD Exacerbation Studies Can Be An Exasperating Experience
As competitors tout comparative data, Boehringer hopes a Nov. 19 advisory committee on its claim for reduction in exacerbations will lead to a broader label.
Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas
After long development haul, PDE-4 inhibitor finally gets adopted by a commercial parent, ahead of approval.